Lexeo Therapeutics (LXEO) EBIT: 2022-2023
Historic EBIT for Lexeo Therapeutics (LXEO) over the last 1 years, with Dec 2023 value amounting to -$15.0 million.
- Lexeo Therapeutics' EBIT rose 1.47% to -$15.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$68.5 million, marking a year-over-year change of. This contributed to the annual value of -$105.8 million for FY2024, which is 54.37% down from last year.
- Latest data reveals that Lexeo Therapeutics reported EBIT of -$15.0 million as of Q4 2023, which was up 26.14% from -$20.3 million recorded in Q3 2023.
- Lexeo Therapeutics' EBIT's 5-year high stood at -$14.0 million during Q2 2023, with a 5-year trough of -$20.3 million in Q3 2023.
- Moreover, its 2-year median value for EBIT was -$16.3 million (2022), whereas its average is -$16.9 million.
- The largest annual percentage gain for Lexeo Therapeutics' EBIT in the last 5 years was 1.47% (2023), contrasted with its biggest fall of 15.96% (2023).
- Lexeo Therapeutics' EBIT (Quarterly) stood at -$15.2 million in 2022, then rose by 1.47% to -$15.0 million in 2023.
- Its EBIT was -$15.0 million in Q4 2023, compared to -$20.3 million in Q3 2023 and -$14.0 million in Q2 2023.